MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- Indian - indian pharma
- FRESENIUS KABI ONCO. - ABBOTT INDIA
FRESENIUS KABI ONCO. vs ABBOTT INDIA - Comparison Results
FRESENIUS KABI ONCO. 
Change
Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More
ABBOTT INDIA
Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More
Current Valuations
| FRESENIUS KABI ONCO. | ABBOTT INDIA | FRESENIUS KABI ONCO./ ABBOTT INDIA |
|||
|---|---|---|---|---|---|
| P/E (TTM) | x | 22.1 | 35.9 | 61.6% | View Chart |
| P/BV | x | 3.1 | 9.3 | 33.5% | View Chart |
| Dividend Yield | % | 0.0 | 0.7 | - |
Financials
 FRESENIUS KABI ONCO.  ABBOTT INDIA |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| FRESENIUS KABI ONCO. Mar-13 |
ABBOTT INDIA Mar-18 |
FRESENIUS KABI ONCO./ ABBOTT INDIA |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 176 | 6,110 | 2.9% | |
| Low | Rs | 79 | 3,996 | 2.0% | |
| Sales per share (Unadj.) | Rs | 37.7 | 1,552.2 | 2.4% | |
| Earnings per share (Unadj.) | Rs | 5.1 | 188.8 | 2.7% | |
| Cash flow per share (Unadj.) | Rs | 6.7 | 196.4 | 3.4% | |
| Dividends per share (Unadj.) | Rs | 0 | 55.00 | 0.0% | |
| Dividend yield (eoy) | % | 0 | 1.1 | 0.0% | |
| Book value per share (Unadj.) | Rs | 42.5 | 796.6 | 5.3% | |
| Shares outstanding (eoy) | m | 158.23 | 21.25 | 744.6% | |
| Bonus/Rights/Conversions | - | - | - | ||
| Price / Sales ratio | x | 3.4 | 3.3 | 103.7% | |
| Avg P/E ratio | x | 25.0 | 26.8 | 93.4% | |
| P/CF ratio (eoy) | x | 18.9 | 25.7 | 73.6% | |
| Price / Book Value ratio | x | 3.0 | 6.3 | 47.2% | |
| Dividend payout | % | 0 | 29.1 | 0.0% | |
| Avg Mkt Cap | Rs m | 20,135 | 107,376 | 18.8% | |
| No. of employees | `000 | 1.2 | 3.3 | 34.7% | |
| Total wages/salary | Rs m | 703 | 3,937 | 17.9% | |
| Avg. sales/employee | Rs Th | 5,176.2 | 9,929.3 | 52.1% | |
| Avg. wages/employee | Rs Th | 610.4 | 1,185.1 | 51.5% | |
| Avg. net profit/employee | Rs Th | 699.6 | 1,207.7 | 57.9% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 5,963 | 32,985 | 18.1% | |
| Other income | Rs m | 18 | 1,170 | 1.5% | |
| Total revenues | Rs m | 5,981 | 34,155 | 17.5% | |
| Gross profit | Rs m | 1,430 | 5,245 | 27.3% | |
| Depreciation | Rs m | 258 | 162 | 159.3% | |
| Interest | Rs m | -26 | 38 | -68.1% | |
| Profit before tax | Rs m | 1,216 | 6,215 | 19.6% | |
| Minority Interest | Rs m | 0 | 0 | - | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | -68 | 0 | - | |
| Tax | Rs m | 342 | 2,203 | 15.5% | |
| Profit after tax | Rs m | 806 | 4,012 | 20.1% | |
| Gross profit margin | % | 24.0 | 15.9 | 150.8% | |
| Effective tax rate | % | 28.1 | 35.4 | 79.4% | |
| Net profit margin | % | 13.5 | 12.2 | 111.1% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 5,102 | 22,655 | 22.5% | |
| Current liabilities | Rs m | 2,385 | 6,681 | 35.7% | |
| Net working cap to sales | % | 45.6 | 48.4 | 94.1% | |
| Current ratio | x | 2.1 | 3.4 | 63.1% | |
| Inventory Days | Days | 150 | 65 | 231.6% | |
| Debtors Days | Days | 113 | 29 | 388.6% | |
| Net fixed assets | Rs m | 5,148 | 835 | 616.2% | |
| Share capital | Rs m | 158 | 213 | 74.4% | |
| "Free" reserves | Rs m | 6,556 | 16,715 | 39.2% | |
| Net worth | Rs m | 6,732 | 16,928 | 39.8% | |
| Long term debt | Rs m | 952 | 0 | - | |
| Total assets | Rs m | 10,388 | 24,162 | 43.0% | |
| Interest coverage | x | -45.8 | 163.7 | -28.0% | |
| Debt to equity ratio | x | 0.1 | 0 | - | |
| Sales to assets ratio | x | 0.6 | 1.4 | 42.0% | |
| Return on assets | % | 7.5 | 16.8 | 44.8% | |
| Return on equity | % | 12.0 | 23.7 | 50.5% | |
| Return on capital | % | 14.6 | 36.9 | 39.5% | |
| Exports to sales | % | 74.5 | 0 | - | |
| Imports to sales | % | 24.8 | 0 | - | |
| Exports (fob) | Rs m | 4,441 | NA | - | |
| Imports (cif) | Rs m | 1,477 | NA | - | |
| Fx inflow | Rs m | 5,298 | 369 | 1,437.5% | |
| Fx outflow | Rs m | 1,772 | 3,807 | 46.6% | |
| Net fx | Rs m | 3,525 | -3,438 | -102.5% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 1,274 | 1,527 | 83.4% | |
| From Investments | Rs m | -1,204 | -2,148 | 56.1% | |
| From Financial Activity | Rs m | -196 | -1,024 | 19.1% | |
| Net Cashflow | Rs m | -126 | -1,646 | 7.7% | |
Share Holding
| Indian Promoters | % | 0.0 | 0.0 | - | |
| Foreign collaborators | % | 81.0 | 75.0 | 108.0% | |
| Indian inst/Mut Fund | % | 0.3 | 7.9 | 3.8% | |
| FIIs | % | 9.6 | 0.1 | 9,600.0% | |
| ADR/GDR | % | 0.0 | 0.0 | - | |
| Free float | % | 9.1 | 17.1 | 53.2% | |
| Shareholders | 42,599 | 18,270 | 233.2% | ||
| Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare FRESENIUS KABI ONCO. With: ALEMBIC PHARMA STRIDES PHARMA SCIENCE FDC LTD. ASTRAZENECA PHARMA BIOCON
Compare FRESENIUS KABI ONCO. With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
|
| |
Today's Market
US China Trade War Escalations and Election Results: Volatility Set to Rule(Podcast)
India could be the latest direct victim of the US-China trade war. The increasing escalations have already slowed down global growth.
Related Views on News
ABBOTT INDIA Announces Quarterly Results (3QFY19); Net Profit Up 1.4% (Quarterly Result Update)
Feb 12, 2019 | Updated on Feb 12, 2019For the quarter ended December 2018, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 1.4% YoY). Sales on the other hand came in at Rs 9 bn (up 7.5% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.
ABBOTT INDIA Announces Quarterly Results (2QFY19); Net Profit Up 0.1% (Quarterly Result Update)
Nov 14, 2018 | Updated on Nov 14, 2018For the quarter ended September 2018, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 0.1% YoY). Sales on the other hand came in at Rs 10 bn (up 5.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.
ABBOTT INDIA Announces Quarterly Results (1QFY19); Net Profit Up 70.8% (Quarterly Result Update)
Aug 20, 2018 | Updated on Aug 20, 2018For the quarter ended June 2018, ABBOTT INDIA has posted a net profit of Rs 824 m (up 70.8% YoY). Sales on the other hand came in at Rs 8 bn (up 18.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.
ABBOTT INDIA Announces Quarterly Results (4QFY18); Net Profit Up 137.9% (Quarterly Result Update)
Jul 20, 2018 | Updated on Jul 20, 2018For the quarter ended March 2018, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 137.9% YoY). Sales on the other hand came in at Rs 8 bn (up 10.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
More Views on NewsMost Popular
These Dividend Stocks Could Boost Your Returns Better Than You Can Imagine(Profit Hunter)
May 7, 2019The art of dividend investing is a lot more than investing in companies with high dividend payouts or stocks with high dividend yields...
Limited Upside, Higher Downside(The Honest Truth)
May 6, 2019The market's irrational reaction may present opportunities for a limited period of time.
3 Indian Stocks Replicating Amazon's Successful Strategy(The 5 Minute Wrapup)
May 10, 2019The one critical element that has made Amazon a force to reckon with...
A Simple Checklist for Picking Great Dividend Stocks(Profit Hunter)
May 9, 2019A filtered, neat list of high-dividend stocks with all this dirty work already done for you.
My Top 7 Stocks to Profit from Sensex 100,000(The 5 Minute Wrapup)
May 16, 2019Tanushree Banerjee explains everything you need to know about the Rebirth of India and Sensex 100,000.
More|
| |
FRESENIUS KABI ONCO. SHARE PRICE
Jan 2, 2014 (Close)
TRACK FRESENIUS KABI ONCO.
- Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON FRESENIUS KABI ONCO.
FRESENIUS KABI ONCO. 5-YR ANALYSIS
COMPARE FRESENIUS KABI ONCO. WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.